SLX-100, a novel immediate release formulation of 4-aminopyridine, for the treatment of Spinocerebellar Ataxia 27B (SCA27B), an orphan disease
Saved in:
| Main Author: | Amy Chappell, M.D. |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Neurotherapeutics |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1878747925001655 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Electronystagmography findings in spinocerebellar ataxia type 3 (SCA3) and type 2 (SCA2)
by: Bianca Simone Zeigelboim, et al.
Published: (2011-10-01) -
Clinical and Video-Oculographic Characteristics of Spinocerebellar Ataxia Type 27B (GAA-<i>FGF14</i> Ataxia): A Single-Center Retrospective Study
by: Evgenii Nuzhnyi, et al.
Published: (2024-10-01) -
Inheritance patterns of ATCCT repeat interruptions in spinocerebellar ataxia type 10 (SCA10) expansions.
by: Ivette Landrian, et al.
Published: (2017-01-01) -
Spinocerebellar Ataxia 7: A Report of Unaffected Siblings Who Married into Different SCA 7 Families
by: Fariha Zaheer, et al.
Published: (2014-01-01) -
Cerebral cortical functional hyperconnectivity in a mouse model of spinocerebellar ataxia type 8 (SCA8)
by: Angela K. Nietz, et al.
Published: (2025-03-01)